CG Oncology, Inc. Common stock
CGON · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,139 | $204 | $191 | $10,358 |
| % Growth | 458.3% | 6.8% | -98.2% | – |
| Cost of Goods Sold | $0 | $0 | $15 | $10 |
| Gross Profit | $1,139 | $204 | $176 | $10,348 |
| % Margin | 100% | 100% | 92.1% | 99.9% |
| R&D Expenses | $82,102 | $45,752 | $29,029 | $18,319 |
| G&A Expenses | $33,703 | $9,901 | $6,408 | $4,645 |
| SG&A Expenses | $33,703 | $9,901 | $6,393 | $4,635 |
| Sales & Mktg Exp. | $0 | $0 | -$15 | -$10 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $115,805 | $55,653 | $35,422 | $22,954 |
| Operating Income | -$114,666 | -$55,449 | -$35,246 | -$12,606 |
| % Margin | -10,067.3% | -27,180.9% | -18,453.4% | -121.7% |
| Other Income/Exp. Net | $26,627 | $6,842 | -$197 | -$233 |
| Pre-Tax Income | -$88,039 | -$48,607 | -$35,443 | -$12,839 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$88,039 | -$48,607 | -$35,443 | -$12,839 |
| % Margin | -7,729.5% | -23,827% | -18,556.5% | -124% |
| EPS | -1.41 | -1.02 | -0.66 | -0.28 |
| % Growth | -38.2% | -54.5% | -135.7% | – |
| EPS Diluted | -1.41 | -1.02 | -0.66 | -0.28 |
| Weighted Avg Shares Out | 62,497 | 66,636 | 66,636 | 66,636 |
| Weighted Avg Shares Out Dil | 62,497 | 66,636 | 66,636 | 66,636 |
| Supplemental Information | – | – | – | – |
| Interest Income | $26,624 | $6,904 | $0 | $0 |
| Interest Expense | $0 | $0 | $1 | $451 |
| Depreciation & Amortization | $32 | $17 | $15 | $10 |
| EBITDA | -$114,634 | -$55,432 | -$35,231 | -$12,378 |
| % Margin | -10,064.4% | -27,172.5% | -18,445.5% | -119.5% |